PRM23 Proqolid Database: Where Are We Ten Years After Its Launch?

Abstract

subgroup of patients (Nϭ473) eligible for evaluation under Method II was also evaluated under Method I, to assess differences in results compared with the overall population. Method I yielded higher dose estimates when compared to Method II. This was consistent for the total sample and subgroup. Ustekinumab cost per injection in Method I was estimated up to 68.2% higher than in Method II. Variability in cost estimates across doses was up to 18 times higher in Method I than Method II. CONCLUSIONS: Conducting ustekinumab drug utilization assessments with pharmacy claims requires a methodological adjustment to address multiple doses dispensed on the same claim. Unadjusted assessment may yield artificially high dose and cost estimates. Adjusted assessments offer a more realistic distribution of dose and less variability in cost estimates. The ability to conduct adjusted assessments requires the sample to have Ն 2 ustekinumab prescriptions and sufficient follow-up time.